Opko Health, INC.: directors' dealings · United States · SEC (Form 4)

About Opko Health, INC.

OPKO Health, Inc. (ticker: OPK) is a U.S.-listed healthcare company traded on the NASDAQ in the United States. Headquartered in Miami, Florida, at 4400 Biscayne Boulevard, OPKO presents itself as a fully integrated healthcare platform combining pharmaceuticals, diagnostics, and research-driven drug development. For French-, Belgian- and Swiss-based investors, it is best understood as a hybrid healthcare group: part commercial pharma company, part clinical diagnostics operator, and part biotech with pipeline optionality. The company’s roots trace back to Dr. Phillip Frost, a well-known figure in U.S. biopharma, and OPKO adopted its current name in 2007. Since then, the group has built a diversified model around large healthcare markets rather than relying on a single asset. Its main business lines include Pharmaceuticals, Diagnostics, and Research. In pharmaceuticals, OPKO markets products such as RAYALDEE® and has exposure to NGENLA™ through a partnership model. In diagnostics, the company operates BioReference Laboratories, which OPKO describes as one of the largest full-service clinical reference laboratories in the United States, serving approximately 11 million patients annually. On the innovation side, OPKO is developing next-generation multispecific biologics through its wholly owned subsidiary ModeX Therapeutics. From a competitive standpoint, OPKO operates in highly contested markets where scale, reimbursement, regulatory execution, and scientific differentiation matter. The company’s strategy is not simply to compete as a standalone commercial manufacturer, but to combine recurring operating businesses with partnered development programs and broader scientific collaborations. That approach gives OPKO multiple potential value drivers: diagnostic cash generation, product commercialization, and pipeline milestones. The company has highlighted partnerships with leading organizations including Pfizer, Merck, BARDA, the NIH, Regeneron, CSL Vifor, and Entera Bio, which supports its credibility as a collaborator in advanced healthcare research. Geographically, OPKO has a meaningful international footprint, with operating businesses in the United States, Mexico, Chile, Spain, Ireland, and Israel, and broader commercialization reach through partnerships in additional markets. Recent developments have been particularly important for the investment case. In 2025 and 2026, OPKO reported progress for ModeX programs, including clinical advancement of multispecific antibody candidates and the initiation of a Phase 1 study for a tetraspecific antibody in B-cell lymphomas. The company also expanded its collaboration with Entera Bio to advance an oral long-acting PTH tablet for hypoparathyroidism. In parallel, OPKO continued to reshape its diagnostics portfolio, including the sale of select oncology-related testing assets to Labcorp. Overall, OPKO remains a diversified healthcare story with a mix of established revenues, partnership monetization, and clinical-stage upside on the NASDAQ in the United States.